Aurobindo Pharma Patent-Cliff Exposure & CMS Drug Spending Portfolio

Aurobindo Pharma (East Windsor, NJ): 44 reconciled FDA prescription therapies (0.2% 2025 to 2030 cliff risk), $746.5M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterEast Windsor, NJ
Reconciled FDA Portfolio Therapies44
2025 to 2030 Patent-Cliff Revenue Exposure0.2%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$746.5M
2024 Medicare Part D Spend$507.2M
2024 Medicaid Spend$239.3M
California HCAI SB 17 Filings9 WAC filings (max 736.5% 2-yr change)